RxDoctor Payments Data

James Reed, MD

Child & Adolescent Psychiatry · Longwood, FLNPI 1861699498

Payments from drug & device makers

$825in general payments, 2019–2025

Across 44 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$230
  • E.r. Squibb & Sons, L.L.C.$96
  • Supernus Pharmaceuticals, Inc.$89
  • Otsuka America Pharmaceutical, Inc.$59
  • Lundbeck LLC$58
  • Bausch Health US, LLC$55
  • plus $238 from 7 others

What the payments were for

  • Food & beverage$79897%
  • Education$273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$825 in reported general payments places this provider in the 60th percentile of 206 child & adolescent psychiatry providers in Florida.

See all child & adolescent psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$106,637
Medicare patients
115
Services billed
1,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate13$38,769
Lurasidone Hcl62$28,803
VraylarCariprazine Hcl14$20,989
RexultiBrexpiprazole13$20,623
VyvanseLisdexamfetamine Dimesylate23$13,265
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl62$10,478
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine202$6,751
LinzessLinaclotide12$6,237
Aripiprazole129$4,317
Desvenlafaxine Succinate ErDesvenlafaxine Succinate20$2,947
Olanzapine82$2,508
Methylphenidate Hcl69$2,386
Quetiapine Fumarate149$2,057
Clonazepam192$1,863
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine35$1,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$14$38,76913 claims
AbbVieVraylar, Linzess$230$27,22626 claims
Otsuka America Pharmaceutical, Inc.Rexulti$59$20,62313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 206 child & adolescent psychiatry providers in Florida.

Other child & adolescent psychiatry in Longwood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →